ArticleEuropean journal of nuclear medicine and molecular imaging2018
Ultra-early response assessment in lymphoma treatment: [
Article in European journal of nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- The value of FDG PET/CT imaging in outcome prediction and response assessment of lymphoma patients treated with immunotherapy: a meta-analysis and systematic review.European journal of nuclear medicine and molecular imaging · 2022Pooled it
- Early Whole-Body Diffusion-weighted MRI Helps Predict Long-term Outcome Following Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumors.Radiology. Imaging cancer · 2022Trial
- A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.Leukemia & lymphoma · 2022Trial
- The use of PET/MRI in radiotherapy.Insights into imaging · 2024Review
- Comparison of diffusion-weighted MRI and [European radiology · 2024Review
- Positron emission tomography/magnetic resonance imaging (PET/MRI) vs. gastroscopy: Can it improve detection of extranodal marginal zone lymphomas of the stomach followingExpert review of hematology · 2022Review
- Positron Emission Tomography Molecular Imaging for Phenotyping and Management of Lymphoma.Phenomics (Cham, Switzerland) · 2022Review
- A multidisciplinary consensus on the morphological and functional responses to immunotherapy treatment.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Article
- The prognostic significance of whole-body and spleen MTV (metabolic tumor volume) scanning for patients with diffuse large B cell lymphoma.International journal of clinical oncology · 2021Article
- In Human Visualization of Ibrutinib-Induced CLL Compartment Shift.Cancer immunology research · 2020Article
- MRI and PET/MRI in hematologic malignancies.Journal of magnetic resonance imaging : JMRI · 2020Review
- Computed tomography texture analysis for assessment of chemotherapy response of Hodgkin lymphoma.Medicine · 2020Article
- Performance of Multiparametric Functional Imaging and Texture Analysis in Predicting Synchronous Metastatic Disease in Pancreatic Ductal Adenocarcinoma Patients by Hybrid PET/MR: Initial Experience.Frontiers in oncology · 2020Article
- Very Early Response Evaluation by PET/MR in Patients with Lung Cancer-Timing and Feasibility.Diagnostics (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 2 countries.
Funding
Abstract
purposeTo determine whether, in patients with Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL), [
methodsPatients with histologically proven HL or NHL were included in this prospective IRB-approved study. Patients underwent [
resultsA total of 58 patients (11 with HL and 47 with NHL) with 166 lesions were analysed. Lesion-based mean rates of change in SUVmax, SUVmean, ADCmin, ADCmean, MTV and VOL between baseline and FU-1 were -46.8%, -33.3%, +20.3%, +14%, -46% and -12.8%, respectively, and between baseline and FU-2 were -65.1%, -49%, +50.7%, +32.4%, -61.1% and -24.2%, respectively. These changes were statistically significant (P < 0.01) except for the change in VOL between baseline and FU-1 (P = 0.079).
conclusionIn lymphoma patients, [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.